Riskpilot← Back to searchSign inGet full accessBIOGEN NORWAY AS
ASActiveOrg 980785122Vitaminveien 1A, 0485 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 19998 employeeswww.biogenidec.no
Revenue 2024
NOK 287,9M
+13% vs 2023
EBITDA margin
3.5%
+2% vs 2023
Equity ratio
79.2%
Financial strength
Net profit 2024
NOK 12,1M
+27% vs 2023
| Revenue | NOK 287,9M | +13% |
| EBITDA | NOK 10,1M | +2% |
| Net profit | NOK 12,1M | +27% |
| Total assets | NOK 233,9M | +11% |
| Equity | NOK 185,2M | +7% |
| Employees | 8 | — |
Legal name
BIOGEN NORWAY AS
Org number
980785122
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
18. mai 1999
Share capital
—
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Address
Vitaminveien 1A, 0485 Oslo
Website
www.biogenidec.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 473 440 | 385 429 | 284 385 | 253 925 | 287 946 |
| Staff expenses | −26 840 | −33 317 | −0 | −0 | −0 |
| EBITDA | 23 633 | 18 092 | 9 883 | 9 871 | 10 096 |
| Depreciation & amort. | −317 | −119 | −88 | −134 | −21 |
| EBIT | 23 316 | 17 973 | 9 795 | 9 737 | 10 075 |
| Net financials | 10 | −390 | −231 | 2 455 | 5 401 |
| Profit before tax | 23 326 | 17 583 | 9 564 | 12 192 | 15 476 |
| Tax | 5 135 | 3 878 | −0 | −0 | −0 |
| Net profit | 18 190 | 13 705 | 7 450 | 9 493 | 12 065 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 205 038 | 216 560 | 198 402 | 210 748 | 233 915 |
| Equity | 142 507 | 156 212 | 163 662 | 173 155 | 185 219 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 62 530 | 60 348 | 34 740 | 37 593 | 48 696 |
| Total debt | 62 530 | 60 348 | 34 740 | 37 593 | 48 696 |
EBITDA margin
3.5%
This company
15.8%
Market median
-78% vs market
20202024
Equity ratio
79.2%
This company
38.2%
Market median
+107% vs market
20202024
Return on equity
6.5%
This company
18.4%
Market median
-65% vs market
20202024
Net profit margin
4.2%
This company
8.1%
Market median
-48% vs market
20202024
Asset turnover
1.23×
This company
1.12×
Market median
+10% vs market
20202024
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ML Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2023 | |
| Former (3) | ||
| Board of Directors | 2023 – 2024 | |
| Chairman | 2019 – 2023 | |
| Board of Directors | 2023 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Biogen Idec International Bvi | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIOGEN NORWAY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Lofthus Tangnes | Chief Executive Officer | 0 companies |
| Sergio Ferreira Da Silva Teixeira | Chairman | 0 companies |
| Rune Stenbro-Larsen | Board of Directors | 0 companies |
| Ulf Johan Ström | Chairman | 0 companies |
| Allan Frank Fischer Petersen | Board of Directors | 0 companies |